ZA200006379B - Adjuvant composition and methods for its use. - Google Patents
Adjuvant composition and methods for its use. Download PDFInfo
- Publication number
- ZA200006379B ZA200006379B ZA200006379A ZA200006379A ZA200006379B ZA 200006379 B ZA200006379 B ZA 200006379B ZA 200006379 A ZA200006379 A ZA 200006379A ZA 200006379 A ZA200006379 A ZA 200006379A ZA 200006379 B ZA200006379 B ZA 200006379B
- Authority
- ZA
- South Africa
- Prior art keywords
- volume
- adjuvant composition
- emulsion
- composition
- mla
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 62
- 239000002671 adjuvant Substances 0.000 title claims description 52
- 238000000034 method Methods 0.000 title description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 61
- 239000000839 emulsion Substances 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 25
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 24
- 239000003921 oil Substances 0.000 claims description 18
- 235000019198 oils Nutrition 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 16
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 14
- 230000002238 attenuated effect Effects 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 12
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 11
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 11
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 229920001993 poloxamer 188 Polymers 0.000 claims description 11
- 229940031439 squalene Drugs 0.000 claims description 11
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 229920001400 block copolymer Polymers 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 235000010384 tocopherol Nutrition 0.000 claims description 10
- 229960001295 tocopherol Drugs 0.000 claims description 10
- 229930003799 tocopherol Natural products 0.000 claims description 10
- 239000011732 tocopherol Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- -1 sphingomyelin Chemical compound 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 2
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940099352 cholate Drugs 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 239000002510 pyrogen Substances 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000001698 pyrogenic effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical group 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000000231 atomic layer deposition Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000007402 cytotoxic response Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011046 pyrogen test Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000751119 Mila <angiosperm> Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 2
- 235000019289 ammonium phosphates Nutrition 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 210000002925 A-like Anatomy 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- VOXDTCSXQHOYKC-XGEOUJBZSA-N palmitoyllipid A Chemical compound O[C@H]1[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 VOXDTCSXQHOYKC-XGEOUJBZSA-N 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Biological Depolymerization Polymers (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8467898P | 1998-05-07 | 1998-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200006379B true ZA200006379B (en) | 2002-01-07 |
Family
ID=22186530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200006379A ZA200006379B (en) | 1998-05-07 | 2000-11-07 | Adjuvant composition and methods for its use. |
Country Status (20)
Country | Link |
---|---|
US (2) | US6630161B1 (hu) |
EP (1) | EP1075276B1 (hu) |
JP (1) | JP2002513773A (hu) |
KR (1) | KR100682154B1 (hu) |
CN (2) | CN101219217A (hu) |
AT (1) | ATE375803T1 (hu) |
AU (1) | AU755445B2 (hu) |
BR (1) | BR9910269A (hu) |
CA (1) | CA2330610A1 (hu) |
CY (1) | CY1107265T1 (hu) |
DE (1) | DE69937343T2 (hu) |
DK (1) | DK1075276T3 (hu) |
ES (1) | ES2296390T3 (hu) |
HK (1) | HK1039072A1 (hu) |
HU (1) | HU225844B1 (hu) |
NO (1) | NO20005596L (hu) |
NZ (1) | NZ508013A (hu) |
PT (1) | PT1075276E (hu) |
WO (1) | WO1999056776A2 (hu) |
ZA (1) | ZA200006379B (hu) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
US6630161B1 (en) * | 1998-05-07 | 2003-10-07 | Ribi Immunochem Research, Inc. | Adjuvant composition and methods for its use |
DE19859045A1 (de) | 1998-12-21 | 2000-06-29 | Fresenius Pharma Austria Gmbh | Emulsion vom Typ Öl in Wasser mit Schutzwirkung gegen Peroxidationsschäden an menschlichen Organen, deren Herstellung und Verwendung |
US7915238B2 (en) * | 1999-02-01 | 2011-03-29 | Eisai R & D Management Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US20040006242A1 (en) * | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US20030031684A1 (en) * | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
US7470791B2 (en) | 2003-03-10 | 2008-12-30 | Nycomed Gmbh | Process for the preparation of roflumilast |
SI1651265T1 (sl) | 2003-07-24 | 2008-10-31 | Merial Ltd | Formulacije cepiva, ki obsegajo emulzijo olje v vodi |
ZA200700457B (en) | 2004-06-15 | 2008-08-27 | New York Blood Ct Inc | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
FR2873386B1 (fr) | 2004-07-22 | 2011-01-14 | Agence Francaise De Securite Sanitaire Des Aliments Afssa | Composition vaccinale contre le rhodococcus equi |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
CN1320924C (zh) * | 2005-01-07 | 2007-06-13 | 邢为藩 | 一种自乳化疫苗佐剂及其制备方法 |
ES2421916T3 (es) | 2005-03-16 | 2013-09-06 | Nycomed Gmbh | Forma farmacéutica de sabor enmascarado que contiene roflumilast |
AU2006226458B2 (en) | 2005-03-23 | 2012-08-30 | Glaxosmithkline Biologicals S.A. | Novel composition |
WO2006116423A2 (en) | 2005-04-26 | 2006-11-02 | Eisai Co., Ltd | Compositions and methods for cancer immunotherapy |
US20070292418A1 (en) * | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
WO2007052155A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
JP2009514844A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
US7848801B2 (en) | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
EP2007765B1 (en) * | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
US20100010217A1 (en) * | 2006-03-23 | 2010-01-14 | Valiante Nicholas M | Methods for the preparation of imidazole-containing compounds |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
US20100015168A1 (en) | 2006-06-09 | 2010-01-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
KR101696727B1 (ko) | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP3456348A1 (en) | 2006-09-11 | 2019-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
SI2068918T1 (sl) | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
CA2671629C (en) | 2006-12-06 | 2017-08-15 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
EP2123259A1 (en) * | 2007-01-16 | 2009-11-25 | Hokkaido University | Liposome preparation for iontophoresis having antioxidant component encapsulated therein |
PE20090146A1 (es) | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
HUE025149T2 (hu) | 2007-08-02 | 2016-01-28 | Biondvax Pharmaceuticals Ltd | Multimer multiepitóp influenza vakcinák |
WO2009039628A1 (en) | 2007-09-27 | 2009-04-02 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
AU2009227674C1 (en) | 2008-03-18 | 2015-01-29 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
JP5715051B2 (ja) | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
US20110236470A1 (en) | 2008-12-03 | 2011-09-29 | Yaffa Mizrachi Nebenzahl | GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
PL2396032T3 (pl) | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
CN102438650A (zh) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | 衣原体抗原 |
CN109248313B (zh) | 2009-04-14 | 2023-01-17 | 葛兰素史密丝克莱恩生物有限公司 | 用于免疫接种以抵御金黄色葡萄球菌的组合物 |
RU2732574C2 (ru) | 2009-06-05 | 2020-09-21 | Инфекшес Дизиз Рисерч Инститьют | Синтетические глюкопиранозиллипидные адъюванты |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
ES2662716T3 (es) | 2009-07-07 | 2018-04-09 | Glaxosmithkline Biologicals Sa | Inmunógenos conservados de Escherichia coli |
MX2012000734A (es) | 2009-07-16 | 2012-01-27 | Novartis Ag | Inmunogenos destoxificados de escherichia coli. |
RU2555342C2 (ru) | 2009-09-10 | 2015-07-10 | Мериал Лимитед | Новые вакцинные составы, включающие сапонинсодержащие адъюванты |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E.coliキャリアタンパク質に結合体化した多糖免疫原 |
WO2011112871A1 (en) | 2010-03-11 | 2011-09-15 | Immune Design Corp. | Vaccines for pandemic influenza |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
CA2832307A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2012149307A2 (en) | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
JP6240077B2 (ja) | 2011-10-06 | 2017-11-29 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
US20150044251A1 (en) | 2011-12-23 | 2015-02-12 | Novartis Ag | Stable compositions for immunising against staphylococcus aureus |
CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
RU2014140521A (ru) | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
EP3492095A1 (en) | 2012-04-01 | 2019-06-05 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
GB201212010D0 (en) * | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
HUE044211T2 (hu) | 2012-08-31 | 2019-10-28 | Glaxosmithkline Biologicals Sa | Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék |
US20150203543A1 (en) | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
EP2903650B1 (en) | 2012-10-02 | 2018-04-04 | GlaxoSmithKline Biologicals SA | Nonlinear saccharide conjugates |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
SG11201502599TA (en) | 2012-10-12 | 2015-05-28 | Glaxosmithkline Biolog Sa | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
PL2925355T3 (pl) | 2012-11-30 | 2018-06-29 | Glaxosmithkline Biologicals S.A. | Antygeny pseudomonas i połączenia antygenów |
BR112015014250A2 (pt) | 2012-12-18 | 2017-07-11 | Glaxosmithkline Biologicals Sa | método para imunizar um bebê, vacina de combinação e, kit |
CA2903345A1 (en) * | 2013-03-19 | 2014-09-25 | Biotech Tools S.A. | Allergen preparation |
AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
CA2944768C (en) | 2014-04-03 | 2022-08-30 | Biondvax Pharmaceuticals Ltd. | Compositions of multimeric-multiepitope influenza polypeptides and their production |
CN107405395A (zh) * | 2015-03-17 | 2017-11-28 | 红杉科学有限公司 | 疫苗与佐剂的组合物以及治疗尿路感染的方法 |
EP3069729A1 (en) | 2015-03-17 | 2016-09-21 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
JP6830070B2 (ja) | 2015-07-07 | 2021-02-17 | セキラス ユーケー リミテッドSeqirus UK Limited | インフルエンザ効力アッセイ |
KR101996538B1 (ko) * | 2017-02-13 | 2019-07-04 | 단디바이오사이언스 주식회사 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
US20210340185A1 (en) | 2018-08-29 | 2021-11-04 | Centre Hospitalier Universitaire Vaudois | Ebola vaccine compositions and methods of using same |
SG11202105787QA (en) * | 2018-12-26 | 2021-06-29 | Sumitomo Dainippon Pharma Co Ltd | Preparation including vaccine adjuvant |
JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
CN115300490B (zh) * | 2021-05-07 | 2024-04-16 | 安徽远望乐桓药业有限公司 | 包含角鲨烯和甘露醇的药物组合物及其用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258029A (en) * | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
ES502788A0 (es) * | 1981-06-04 | 1982-04-01 | Landerlan Sa Lab | Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4857318A (en) * | 1983-11-07 | 1989-08-15 | Syntex (U.S.A.) Inc. | Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis |
US5948769A (en) * | 1984-01-28 | 1999-09-07 | Ismail; Roshdy | Agent for treating heart diseases |
US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
US5376369A (en) * | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
JPS63152327A (ja) * | 1987-11-20 | 1988-06-24 | Toyama Chem Co Ltd | 脂肪乳剤から成る溶血防止用組成物を含有する製剤 |
EP0324455A3 (en) * | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
HU198843B (en) * | 1988-02-08 | 1989-12-28 | Frigyes Kovacs | Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH02152931A (ja) * | 1988-12-02 | 1990-06-12 | Green Cross Corp:The | B型肝炎ワクチン |
US5171737A (en) * | 1989-03-03 | 1992-12-15 | The Liposome Company, Inc. | Emulsions |
US5858769A (en) * | 1989-05-15 | 1999-01-12 | Akzo Nobel N.V. | Device for detecting microorganisms |
HU212924B (en) * | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) * | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
DE4019062A1 (de) * | 1989-08-30 | 1991-03-07 | Kali Chemie Ag | Stabilisierung von perfluorcarbonemulsionen und als emulsionsstabilisierende zusaetze verwendbare perfluorierte heterocyclische verbindungen |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5324512A (en) * | 1990-12-26 | 1994-06-28 | The Population Council | [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses |
US5387421A (en) * | 1991-01-31 | 1995-02-07 | Tsrl, Inc. | Multi stage drug delivery system |
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
PT705109E (pt) * | 1993-05-25 | 2001-02-28 | American Cyanamid Co | Adjuvantes para vacinas contra virus sinciciais respiratorios |
US5773011A (en) * | 1993-09-27 | 1998-06-30 | Gerbu Biotechnik Gmbh | Method of preparing a synergistic immunological adjuvant formulation |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2715843B1 (fr) * | 1994-02-09 | 1996-04-12 | Oreal | Compositions cosmétiques antisolaires, procédé de préparation et utilisation. |
FR2716372B1 (fr) * | 1994-02-18 | 1996-04-12 | Oreal | Compositions cosmétiques antisolaires stables, fluides et/ou fluidifiables, procédé de préparation et utilisation. |
AU1566095A (en) * | 1994-02-24 | 1995-09-11 | Micro-Pak, Inc. | Vaccines containing paucilamellar lipid vesicles as immunological adjuvants |
FR2716622B1 (fr) * | 1994-02-28 | 1996-04-12 | Oreal | Compositions cosmétiques autobronzantes à base de dihydroxyacétone, procédé de préparation et utilisation. |
AU3533395A (en) * | 1994-09-30 | 1996-04-26 | Takeda Chemical Industries Ltd. | Oral sustained-release preparation |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9422990D0 (en) * | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Immunogenic compositions |
IL117773A (en) * | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
EP0852941B1 (de) * | 1996-12-13 | 2003-05-14 | Vesifact Ag | Kosmetische Präparate in Form einer Nanodispersion |
WO1998053799A2 (en) * | 1997-05-28 | 1998-12-03 | Jenner Biotherapies, Inc. | Immunogenic compositions |
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
US6630161B1 (en) * | 1998-05-07 | 2003-10-07 | Ribi Immunochem Research, Inc. | Adjuvant composition and methods for its use |
DE69920380T2 (de) * | 1998-12-18 | 2005-11-17 | Shin-Etsu Chemical Co., Ltd. | Organopolysiloxan Öl-in-Wasser Emulsion und Verfahren zur Herstellung |
US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
US6551598B2 (en) * | 2000-01-21 | 2003-04-22 | Merial | Vaccination against canine herpesvirosis and vaccines therefor |
-
1999
- 1999-05-07 US US09/307,321 patent/US6630161B1/en not_active Expired - Fee Related
- 1999-05-07 NZ NZ508013A patent/NZ508013A/en unknown
- 1999-05-07 CN CNA200810008718XA patent/CN101219217A/zh active Pending
- 1999-05-07 DE DE69937343T patent/DE69937343T2/de not_active Expired - Fee Related
- 1999-05-07 CN CN99807591A patent/CN1306438A/zh active Pending
- 1999-05-07 ES ES99922832T patent/ES2296390T3/es not_active Expired - Lifetime
- 1999-05-07 AT AT99922832T patent/ATE375803T1/de not_active IP Right Cessation
- 1999-05-07 CA CA002330610A patent/CA2330610A1/en not_active Abandoned
- 1999-05-07 WO PCT/US1999/009978 patent/WO1999056776A2/en active IP Right Grant
- 1999-05-07 DK DK99922832T patent/DK1075276T3/da active
- 1999-05-07 JP JP2000546800A patent/JP2002513773A/ja active Pending
- 1999-05-07 KR KR1020007012438A patent/KR100682154B1/ko not_active IP Right Cessation
- 1999-05-07 PT PT99922832T patent/PT1075276E/pt unknown
- 1999-05-07 EP EP99922832A patent/EP1075276B1/en not_active Expired - Lifetime
- 1999-05-07 BR BR9910269-2A patent/BR9910269A/pt not_active Application Discontinuation
- 1999-05-07 AU AU39737/99A patent/AU755445B2/en not_active Ceased
- 1999-05-07 HU HU0101804A patent/HU225844B1/hu not_active IP Right Cessation
-
2000
- 2000-11-06 NO NO20005596A patent/NO20005596L/no not_active Application Discontinuation
- 2000-11-07 ZA ZA200006379A patent/ZA200006379B/en unknown
-
2002
- 2002-02-01 HK HK02100782.0A patent/HK1039072A1/zh unknown
-
2003
- 2003-06-10 US US10/459,308 patent/US20030215497A1/en not_active Abandoned
-
2008
- 2008-01-10 CY CY20081100035T patent/CY1107265T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0101804A3 (en) | 2003-11-28 |
KR100682154B1 (ko) | 2007-02-12 |
NZ508013A (en) | 2003-08-29 |
BR9910269A (pt) | 2001-01-09 |
HU225844B1 (en) | 2007-10-29 |
CN1306438A (zh) | 2001-08-01 |
CA2330610A1 (en) | 1999-11-11 |
DK1075276T3 (da) | 2008-02-11 |
NO20005596D0 (no) | 2000-11-06 |
EP1075276B1 (en) | 2007-10-17 |
HUP0101804A2 (hu) | 2001-11-28 |
DE69937343T2 (de) | 2008-07-24 |
DE69937343D1 (de) | 2007-11-29 |
KR20010043404A (ko) | 2001-05-25 |
JP2002513773A (ja) | 2002-05-14 |
WO1999056776A3 (en) | 2000-01-06 |
AU3973799A (en) | 1999-11-23 |
PT1075276E (pt) | 2008-01-22 |
HK1039072A1 (zh) | 2002-04-12 |
CN101219217A (zh) | 2008-07-16 |
AU755445B2 (en) | 2002-12-12 |
NO20005596L (no) | 2001-01-05 |
CY1107265T1 (el) | 2012-11-21 |
US6630161B1 (en) | 2003-10-07 |
ATE375803T1 (de) | 2007-11-15 |
ES2296390T3 (es) | 2008-04-16 |
US20030215497A1 (en) | 2003-11-20 |
WO1999056776A2 (en) | 1999-11-11 |
EP1075276A2 (en) | 2001-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU755445B2 (en) | Adjuvant composition and methods for its use | |
EP0971739B1 (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
EP1194166B1 (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
JP2003502388A5 (hu) | ||
US4395394A (en) | Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants | |
US4310550A (en) | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants | |
MXPA00010931A (en) | Adjuvant composition and methods for its use | |
AU2916302A (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid | |
MXPA06011569A (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
MXPA99009052A (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |